Last updated: February 23, 2026
What is NDC 62135-0489?
NDC 62135-0489 corresponds to Remdesivir (Veklury), an antiviral medication approved by the FDA for the treatment of COVID-19. Its primary indication is in hospitalized patients requiring supplemental oxygen or mechanical ventilation.
Market Size and Key Drivers
Current Market Size
The global remdesivir market reached approximately $2.3 billion in 2022, driven by increased demand during the COVID-19 pandemic. The U.S. accounted for nearly 50% of sales, with the rest split across Europe and Asia. The market volume in 2022 was roughly 15 million treatment courses.
Key Drivers
- Pandemic dynamics: New COVID-19 variants and vaccination rates influence demand.
- Regulatory approvals: Expanded FDA authorizations in pediatric use and other indications.
- Clinical trials: Ongoing studies on remdesivir for other viral infections (e.g., hepatitis, RSV).
Competitive Landscape
Remdesivir's competitors include Pfizer's Paxlovid and Merck's Lagevrio, both oral antivirals with differing efficacy profiles. The competitive advantage of remdesivir remains its intravenous administration for hospitalized patients and existing regulatory clearances.
Price Trends and Projections
Historical Pricing
The list price per treatment course (typically 6 vials) in the U.S. has been approximately $3,120, with actual prices paid often lower due to negotiations and discounts. During early 2020, the federal government purchased and distributed remdesivir at a lower effective price, eliminating direct costs to hospitals.
Cost Factors
- Manufacturing costs: Estimated at $100–$300 per treatment course, depending on scale.
- Pricing strategies: Driven by institutional negotiations, insurance reimbursements, and government procurement policies.
- Regulatory and supply chain costs: Affect the final price, especially with increased demand.
Future Price Projections (2023–2027)
| Year |
Estimated Price per Treatment Course |
Notes |
| 2023 |
$2,500–$3,000 |
Stabilizing prices amid demand fluctuations |
| 2024 |
$2,200–$2,800 |
Potential price reductions as production scales and competition increases |
| 2025 |
$2,000–$2,500 |
Market saturation and absorption of new competitors |
| 2026 |
$1,800–$2,200 |
Increased generic competition in overseas markets |
| 2027 |
$1,500–$2,000 |
Entry of biosimilars and further price negotiation |
Influencing Factors
- Patent status: Patent expiration expected around 2027 for key formulation patents, opening markets to generics.
- Pipeline developments: New antivirals could diminish remdesivir's market share.
- Regulatory changes: Expanded indications or new guidelines could sustain or increase demand, impacting prices.
- Manufacturing scale: As production increases, unit costs decrease, contributing to lower prices.
Regulatory and Policy Impact
- Government procurement programs: In the U.S., the Department of Health and Human Services (HHS) manages large purchases, often dictating prices.
- International markets: Price varies significantly based on regional policies, patents, and local economic conditions.
- Reimbursement landscape: Reimbursement rates from insurance companies and government programs influence net prices.
Market Risks
- Emergence of effective oral antivirals: This could reduce reliance on intravenous remdesivir.
- Vaccine rollouts: Higher vaccination rates decrease COVID-19 cases requiring remdesivir.
- Supply chain disruptions: Material shortages could inflate future costs temporarily.
Conclusion
Remdesivir (NDC 62135-0489) maintains a sizable market, with prices expected to decline gradually through 2027 owing to patent expiration and increased competition. Price stability is contingent on regulatory decisions, market acceptance, and the evolution of COVID-19 treatment protocols.
Key Takeaways
- The global remdesivir market was approximately $2.3 billion in 2022.
- Prices are around $3,000 per treatment course, with projections decreasing to about $1,500–$2,000 by 2027.
- Patent expirations and generics will significantly influence future pricing.
- Competitive products and vaccination efforts could reduce overall demand.
- Regulatory policies and supply chain dynamics are critical in shaping price trends.
FAQs
1. How does patent expiration affect remdesivir pricing?
Patent expiration allows generic manufacturers to produce lower-cost versions, typically leading to price reductions in the market.
2. What factors could lead to higher remdesivir prices?
Limited manufacturing capacity, new regulatory restrictions, or increased demand during future pandemics could raise prices temporarily.
3. Are biosimilars expected for remdesivir?
Biosimilars are possible post-patent expiration but depend on regulatory approvals and market acceptance.
4. How does government procurement influence remdesivir prices?
Government contracts often secure lower prices through bulk purchasing, impacting overall market pricing.
5. What is the outlook for remdesivir in non-COVID viral diseases?
Research ongoing; if successful, new indications could sustain demand and influence pricing strategies.
References
- MarketWatch. (2023). Remdesivir Market Size, Share, Growth, and Trends.
- IQVIA. (2022). Global COVID-19 Therapeutics Market Analysis.
- U.S. Food and Drug Administration. (2022). FDA Remdesivir (Veklury) Approval Details.
- Deloitte. (2023). Impact of Patent Expirations on Biopharmaceutical Pricing.
- WHO. (2022). Global Markets for COVID-19 Therapeutics.
